Monthly Archives: November 2026


Expecting a baby? Looking for ways to learn more about your baby's chromosomal health during pregnancy? MyAfroDNA now offers Rapid Prenatal Aneuploidy Testing, a non-invasive genetic screening service designed to help expectant mothers and healthcare providers gain early insights into selected chromosomal conditions.Pregnancy comes with many questions, and having access to relevant health information can make a difference in how expectant parents and their healthcare providers navigate the journey.Advances in genetic science have made it possible to screen for certain chromosomal abnormalities during pregnancy without invasive procedures.





One such development is Non-Invasive Prenatal Testing (NIPT). At MyAfroDNA, we are making this technology more accessible through our Rapid Aneuploidy Testing service, providing expectant mothers and healthcare facilities in Nigeria with access to specialised prenatal genetic screening.With a simple blood sample from the mother and results available within seven days, the service offers an additional source of genetic information to support informed conversations and pregnancy care.What Is Rapid Aneuploidy Testing?Aneuploidy occurs when a cell has an abnormal number of chromosomes. Some chromosomal abnormalities can affect a baby's development and are associated with genetic conditions.





MyAfroDNA's Rapid Aneuploidy Testing uses Non-Invasive Prenatal Testing (NIPT), which analyses cell-free DNA circulating in the mother's bloodstream to screen for selected chromosomal abnormalities in the developing baby.Unlike invasive prenatal diagnostic procedures, NIPT requires a blood sample from the pregnant mother.





The test screens for:





- Trisomy 21 (Down syndrome): A chromosomal condition caused by an additional copy of chromosome 21.





- Trisomy 18 (Edwards syndrome): A condition associated with an additional copy of chromosome 18.





- Trisomy 13 (Patau syndrome): A condition associated with an additional copy of chromosome 13.





- Sex chromosome abnormalities: Including conditions such as Turner syndrome.NIPT is a screening test, not a diagnostic test. It estimates the likelihood of selected chromosomal conditions but cannot confirm whether a baby has a particular condition. A high-risk result should be discussed with a qualified healthcare professional, who may recommend further diagnostic testing.





Why Consider Prenatal Aneuploidy Testing?





For expectant mothers, prenatal genetic screening can provide additional information about a developing baby's chromosomal health. MyAfroDNA's Rapid Aneuploidy Testing offers:





1. Non-invasive sample collection. The test requires a blood sample from the pregnant mother, avoiding the need for an invasive procedure to obtain the sample for screening.





2. Early genetic insightsScreening can provide information about the likelihood of selected chromosomal abnormalities during pregnancy.





3. Timely resultsMyAfroDNA offers a turnaround time of approximately seven days, subject to sample acceptance and applicable assay requirements.





4. Support for informed decisionsThe results can help expectant mothers and their healthcare providers determine appropriate next steps in pregnancy care.





5. Expert supportOur team provides guidance throughout the testing process.For Expectant Mothers: How to Access the TestYou do not have to navigate the process alone. MyAfroDNA works with healthcare providers to make prenatal aneuploidy screening accessible through a straightforward referral and sample collection process.





Here is how it works:





1. Contact MyAfroDNA: Express your interest in prenatal aneuploidy testing.





2. Get referred to a partner clinic: Our team will guide you to a participating healthcare facility.





3. Sample collection: A blood sample is collected at the partner clinic.





4. Laboratory analysis: Your sample is sent to MyAfroDNA for processing and analysis.





5. Receive your results: Results are made available within approximately seven days, subject to applicable testing requirements.Interested in getting tested? Contact MyAfroDNA to enquire about the service, available partner clinics and how to book your test. Email: info@myafrodna.com





Are you a Healthcare Providers? Partner with MyAfroDNA for Rapid Aneuploidy Testing





We recognise that obstetricians, gynaecologists, fertility specialists, IVF clinics and other reproductive healthcare professionals play an important role in helping expectant mothers access appropriate prenatal screening. MyAfroDNA is inviting healthcare providers and reproductive health facilities across Nigeria to explore partnership opportunities for Rapid Aneuploidy Testing.Through this collaboration, healthcare facilities can refer patients for testing and facilitate sample collection, while MyAfroDNA provides laboratory testing and support.





Benefits of Partnering with MyAfroDNA





- Access to specialised prenatal aneuploidy screening.





- Reliable laboratory support.





- A seven-day results turnaround, subject to sample acceptance and assay requirements.





- A structured referral and sample collection workflow.





- Technical guidance and support throughout the testing process.





Who Can Partner? We welcome expressions of interest from:- Fertility centres and IVF clinics.- Obstetricians and gynaecologists.- Reproductive medicine specialists.- Hospitals and maternal healthcare facilities.- Diagnostic and reproductive health centres.





Interested in becoming a MyAfroDNA partner? Complete our partnership application to tell us about your facility, available sample collection capabilities and interest in collaborating. At MyAfroDNA, we believe that access to genetic insights should be an important part of conversations about healthcare and well-being.By bringing together biotechnology, laboratory expertise and healthcare providers, we are working to expand access to specialised genetic testing services in Nigeria. Whether you are an expectant mother seeking additional information about your baby's chromosomal health or a healthcare professional looking to expand the services available to your patients, MyAfroDNA is ready to explore how we can support you.



Could a molecule found in the venom of a southern African scorpion contribute to the development of new treatments for antibiotic-resistant infections?





Researchers at the University of Pretoria are investigating this possibility through Opis16a, a synthetic antimicrobial peptide derived from a molecule originally identified in the venom of Opistophthalmus carinatus, a scorpion native to southern Africa.From scorpion venom to antimicrobial researchOpis16a is a shortened version of a naturally occurring peptide called opistoporin 1. Researchers investigated its potential against drug-resistant bacteria, particularly Gram-negative pathogens.In laboratory experiments, Opis16a inhibited all 12 bacterial strains tested. These included multidrug-resistant strains of Acinetobacter baumannii, a hospital-associated bacterium capable of causing serious bloodstream, respiratory and wound infections.Unlike conventional antibiotics that often target specific bacterial processes, Opis16a works by disrupting bacterial cell membranes. Its positively charged structure allows it to interact with negatively charged bacterial surfaces, damaging their membranes and ultimately killing the cells.





The researchers also investigated its effects in an early infection model using Galleria mellonella (wax moth) larvae. At a tested dose of 10 mg/kg, 87% of larvae treated with Opis16a survived.Why does this discovery matter?Antimicrobial resistance (AMR) is a growing global health challenge. The ability of bacteria to survive treatments that previously controlled them makes infections increasingly difficult to manage.The search for new antimicrobial compounds is therefore essential. Natural biological resources, including plants, microorganisms and animal venoms, offer valuable starting points for drug discovery.This research demonstrates how African biodiversity can contribute to molecular innovation and the development of potential antimicrobial candidates.What happens next?Despite the encouraging findings, Opis16a is still experimental. Researchers must investigate its stability in wound environments, potential toxicity, manufacturing costs and effectiveness in more advanced animal models before human clinical trials can be considered.





The discovery is a reminder that biodiversity is not only an ecological resource. It can also be a source of scientific knowledge and future medical innovation.





Original research: "Scorpion venom-derived Opis16a shows potent membrane-destabilising Gram-negative activity and promising in vivo topical efficacy" (https://doi.org/10.1038/s44259-026-00266-9).





Additional reading: "Nature Africa – Can a scorpion-venom peptide tackle drug-resistant wound infections?" (https://www.nature.com/articles/d44148-026-00345-z).MyAfroDNA | Science, genetics and African health innovation.